Plasma glycoproteomic biomarkers identify metastatic melanoma patients with reduced clinical benefit from immune checkpoint inhibitor therapy.
Pickering C, Aiyetan P, Xu G, Mitchell A, Rice R, Najjar YG, Markowitz J, Ebert LM, Brown MP, Tapia-Rico G, Frederick D, Cong X, Serie D, Lindpaintner K, Schwarz F, Boland GM.
Pickering C, et al. Among authors: najjar yg.
Front Immunol. 2023 Jun 14;14:1187332. doi: 10.3389/fimmu.2023.1187332. eCollection 2023.
Front Immunol. 2023.
PMID: 37388743
Free PMC article.